Evelyn Partners Investment Management LLP Raises Holdings in Danaher Corporation $DHR

Evelyn Partners Investment Management LLP increased its position in shares of Danaher Corporation (NYSE:DHR) by 1,105.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 90,751 shares of the conglomerate’s stock after buying an additional 83,224 shares during the period. Danaher comprises approximately 0.8% of Evelyn Partners Investment Management LLP’s holdings, making the stock its 29th largest holding. Evelyn Partners Investment Management LLP’s holdings in Danaher were worth $17,927,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Red Tortoise LLC increased its position in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares during the period. Ramirez Asset Management Inc. bought a new position in shares of Danaher during the second quarter valued at approximately $40,000. Costello Asset Management INC purchased a new position in Danaher during the first quarter valued at approximately $41,000. Strengthening Families & Communities LLC raised its stake in Danaher by 81.4% in the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after buying an additional 114 shares in the last quarter. Finally, Saudi Central Bank purchased a new stake in Danaher during the first quarter worth $52,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of Danaher stock opened at $227.34 on Friday. The company has a 50 day moving average price of $208.58 and a 200 day moving average price of $201.97. The firm has a market capitalization of $160.58 billion, a P/E ratio of 46.88, a PEG ratio of 3.28 and a beta of 0.81. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. Danaher’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.71 EPS. Sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio is presently 26.39%.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 30,248 shares of company stock worth $6,609,663. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DHR. Deutsche Bank Aktiengesellschaft lifted their price target on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Evercore ISI lifted their target price on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Barclays boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Robert W. Baird set a $247.00 price target on shares of Danaher in a report on Wednesday, October 22nd. Finally, Redburn Partners set a $220.00 price objective on shares of Danaher in a research note on Wednesday, October 8th. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.